Alnylam blames the Inflation Reduction Act for a PhIII cut — would it have sold enough for negotiations?
Alnylam Pharmaceuticals, the pharma market’s leader in RNAi therapies, reported its third quarter earnings Thursday, updating shareholders on its pipeline progress and initial sales figures for the recently approved vutrisiran (marketed as Amvuttra).
But tucked away near the bottom of its report, the company revealed it would scrap plans to launch a Phase III trial for vutrisiran in the rare Stargardt disease, appearing to blame President Joe Biden’s Inflation Reduction Act in the process.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.